Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database

Keisuke Mine, Takehiro Kawashiri, Mizuki Inoue, Daisuke Kobayashi, Kohei Mori, Shiori Hiromoto, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe

Research output: Contribution to journalArticlepeer-review


(1) Background: Oxaliplatin is used as first-line chemotherapy not only for colorectal cancer but also for gastric and pancreatic cancers. However, it induces peripheral neuropathy with high frequency as an adverse event, and there is no effective preventive or therapeutic method. (2) Methods: The effects of omeprazole, a proton pump inhibitor (PPI), on oxaliplatin-induced peripheral neuropathy (OIPN) was investigated using an in vivo model and a real-world database. (3) Results: In a rat model, oxaliplatin (4 mg/kg, i.p., twice a week for 4 weeks) caused mechanical hypersensitivity accompanied by sciatic nerve axonal degeneration and myelin sheath disorder. Repeated injection of omeprazole (5-20 mg/kg, i.p., five times per week for 4 weeks) ameliorated these behavioral and pathological abnormalities. Moreover, omeprazole did not affect the tumor growth inhibition of oxaliplatin in tumor bearing mice. Furthermore, clinical database analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) suggests that the group using omeprazole has a lower reporting rate of peripheral neuropathy of oxaliplatin-treated patients than the group not using (3.06% vs. 6.48%, p < 0.001, reporting odds ratio 0.44, 95% confidence interval 0.32-0.61). (4) Conclusions: These results show the preventing effect of omeprazole on OIPN.

Original languageEnglish
JournalInternational journal of molecular sciences
Issue number16
Publication statusPublished - Aug 9 2022


Dive into the research topics of 'Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database'. Together they form a unique fingerprint.

Cite this